Dementia and Alzheimer Disease

Here's some of what is coming soon to NeurologyLive® this week.

Disease-modifying agents will require early detection, including comprehensive evaluation of disease severity and alternative or confounding diagnoses. When the long-awaited moment arrives, when disease-modifying therapies finally are available for ADRDs…will we be ready?

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke and cerebrovascular disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 14, 2023.

The FDA is expected to make a decision by May 10, 2023, whether brexpiprazole will become the first approved therapy for Alzheimer disease agitation.

ARIA-inducing monoclonal antibodies accelerated ventricular enlargement to a point where a striking correlation between ventricular volume and ARIA frequency was observed.

The neurosurgeon at Marcus Neuroscience Institute, Baptist Health, provided perspective on invasive procedures for degenerative conditions and when deep brain stimulation is needed.

Compared with children without posttraumatic headache, those who experienced migraine symptoms following concussion were nearly 3 times more likely to report reliable increases in somatic symptoms.

Positive phase 2 data on CVN424, NETSseq platforms, and CVN417, a novel treatment for Parkinson disease, were presented at AD/PD 2023 International Conference.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis (MS).

Neurology News Network for the week ending April 8, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 7, 2023.

Treatment with neflamapimod was associated with statistically significantly higher functional dynamic connectivity, with almost half of the cohort experiencing a greater than 10% increase over time.

Amyloid clearance was achieved by 75% of participants who received remternetug at doses ranging from 700 to 2800 mg IV Q4Q by day 169.

By the end of the open label long-term extension study, BIIB080 reduced aggregated tau pathology in all dose groups assessed across all brain composites.

Investigators exercised caution when considering administration of antithrombotics or a thrombolytic agent for patients on lecanemab as cases of intracerebral hemorrhage of more than 1cm have been observed.

Here's some of what is coming soon to NeurologyLive® this week.

Statistically significant improvements in several quantitative test measures of episodic memory, attentiveness, and depressive emotional bias were observed in patients treated with clenbuterol and nadolol.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease (PD).

Neurology News Network for the week ending April 1, 2023. [WATCH TIME: 4 minutes]

In honor of Traumatic Brain Injury Month, held on March 2023, get caught up on some of the latest news in traumatic brain injury as the NeurologyLive® team shares some of our data updates.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 31, 2023.

Beth McQuiston, MD, RD, neurologist, and medical director at Abbott, shared her initial reaction to the FDA approval of the blood test for traumatic brain injury and a campaign to bring awareness to concussions.

In total, 302 pharmacodynamic changes due to CT1812 were identified, with 11 Alzheimer-related priority biomarkers altered in comparison with placebo.

Despite a pause in the trial due to the COVID-19 pandemic, patients who opted to continue treatment into the open-label extension demonstrated significant improvements in Parkinson disease dementia symptoms for up to 48 weeks.

At the willingness to pay threshold of $200,000 per QALY gained, the estimated annual value for lecanemab was $35,678 and $37,351 from the payer and societal perspectives, respectively.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 24, 2023.

Here's some of what is coming soon to NeurologyLive® this week.